ValiRx plc

Default features description for sign up page.

Careers

Collaborative Pipeline

Board & Management Team

Privacy Policy

How we work

Strategy & Vision

Updates

Analyst Research

AIM Rule 26

Share Price Information

Reports, AGMs & Presentations

Regulatory News

Webinars

Partnering & Useful Links

Therapeutic Areas

Inaphaea Biolabs

Evaluation Pipeline

Our Pipeline

Home

Contact Us

DM Sans

upload.jpg

This week is Cancer Prevention Action Week, the annual event that raises awareness of cancer and cancer prevention.

At Inaphaea, we work with our partners to find innovative treatments for conditions such as triple-negative breast cancer, prostate, adenocarcinoma, and much more.

Our range of patient derived cells is available for purchasing and through our translational Contract Research Organisation (tCRO™) offering 2D and 3D tissue culture under normoxic and Hypoxic conditions. Co-culture with immune cells is also available from immune oncology applications. We have over 470 PDCs across 66 cancer types including treated and untreated primary and metastatic samples. RNA-Seq data and treatment response data for 50 standard of care drugs is available for around 300 of the PDCs. The PDCs are available for in-vivo research in zebrafish and mouse models through our partners Bioreparia and Xenopat.

Cancer Prevention Week